Point72 Asia Singapore Pte. Ltd. Sells 19,739 Shares of Eli Lilly and Company (NYSE:LLY)

Point72 Asia Singapore Pte. Ltd. reduced its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 91.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,813 shares of the company's stock after selling 19,739 shares during the period. Point72 Asia Singapore Pte. Ltd.'s holdings in Eli Lilly and Company were worth $1,400,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in LLY. Knightsbridge Asset Management LLC boosted its position in shares of Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after acquiring an additional 15 shares during the period. Centerpoint Advisory Group purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $514,000. Kentucky Trust Co bought a new position in shares of Eli Lilly and Company in the fourth quarter worth $834,000. CSM Advisors LLC increased its holdings in shares of Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after purchasing an additional 245 shares during the period. Finally, Proficio Capital Partners LLC raised its position in shares of Eli Lilly and Company by 30.2% in the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock worth $5,202,000 after buying an additional 1,562 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $716.19 on Thursday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market capitalization of $678.76 billion, a PE ratio of 61.16, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The stock's 50 day moving average price is $801.10 and its 200-day moving average price is $808.28. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the previous year, the firm posted $2.58 earnings per share. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.